Naurex Inc. has presented preclinical data demonstrating that GLYX-13, its rapid-acting novel antidepressant, enhances synaptic plasticity, its hypothesized mechanism of action. The data were presented at the 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, FL. In these studies, GLYX-13 also enhanced enrichment of specific genes associated with synaptic plasticity and long-term depression. GLYX-13 is currently in a Phase IIb repeat-dose trial in patien...